CMC gives the first infusion by a non-university based medical practice

For Immediate Release,

June 17, 2021

Columbus, GA – Columbus Memory Center (CMC) is excited to announce the first infusion of the new Alzheimer’s drug, Aduhelm, by a non-university based medical practice. This milestone also represents the first infusion of this FDA approved therapy for Alzheimer’s disease in the Southeastern United States and only the second patient to be treated in the country. The patient, and his family, wish to remain anonymous. However, they would like to share their sense of hope that this historic moment represents: “We feel so very blessed to be selected to receive this new approved drug. There is new hope for so many and we encourage others to seek treatment.”

“We finally have a drug available for Alzheimer’s disease that modifies and slows the illness” notes Dr. Jonathan Liss, director of Columbus Memory Center. “A bright new day has dawned for people in the earliest stages of this illness. We will continue to work tirelessly to change Alzheimer’s disease into a mere nuisance.”

This groundbreaking new drug slows cognitive decline by removing the amyloid beta proteins that disrupt neurotransmission. Not all patients will be eligible for Aduhelm. Those who are not eligible can inquire about research studies with other promising medications. Columbus Memory Center played an important roll in the clinical testing of Aduhelm and continues to help patient’s access FDA approved research trials.